Skip to content
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to […]
Drug developers and investors need to join AI revolution, panel says Read More »
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and
CEOs say market must keep up with the science of gene therapies Read More »
A proposed World Trade Organization (WTO) IP waiver could have scuttled investment in biotech’s new diabetes drug and already impacts the firm’s decisions about
BIO Board member tells Congress WTO IP waivers hurt innovation Read More »
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year. BIO’s
Congressional action BIO wants to see in 2024 Read More »
After two decades of research and development, Sutro Biopharma is still a few years away from seeking market approval for its first drug, a
Loss of tax incentive for R&D threatens biotech innovation Read More »
The Federal Trade Commission (FTC) challenge of more than 100 patent listings registered with the Food and Drug Administration, mostly for devices used to
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
A bill to incentivize production of low-carbon biofuels by ensuring that the environmental benefits of these fuels are measured accurately when assessing tax credits
Bill seeks accurate measures of how well biofuels cut carbon emissions Read More »
Federal Trade Commission (FTC) proposals for new rules to permit more aggressive opposition to mergers would interfere with the economic ecosystem that is essential
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says Read More »
